Alexander Shulgin Research Institute
Also known as: ASRI
The Alexander Shulgin Research Institute (ASRI) was founded in 2021 by Dr. Nicholas Cozzi, Dr. Paul Daley, and the late Ann Shulgin, continuing the legacy of chemist Alexander Shulgin. The institute maintains the Shulgin Vault — a repository of over 500 compounds synthesized by Shulgin and ASRI scientists. Lead candidate ASR-3001 (5-MeO-iPALT) is an orally active, fast-acting tryptamine with a mild internal psychedelic profile and no visual hallucinations, near IND-ready for psychiatric disorders. ASR-2001 is a non-hallucinogenic compound producing mental clarity.
Drug Pipeline
2ASR-3001 (5-MeO-iPALT)
Orally active 5-HT2A agonist tryptamine. Fast-acting (onset 6-15 min), short-duration (90-150 min). Internal psychedelic state with no visual hallucinations. Near IND filing as of 2025.
ASR-2001
Non-hallucinogenic compound producing a 'focusing-type state of mental clarity' without psychostimulant effects.
Quick Facts
- Type
- Non-Profit
- Founded
- 2021
- Lead Stage
- Pre-clinical
- Website
- Visit